Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ACADIA Pharmaceuticals Inc. - Common Stock
(NQ:
ACAD
)
19.97
+0.02 (+0.10%)
Delayed Quote
Updated: 10:01 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ACADIA Pharmaceuticals Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
August 25, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Affordable Growth Stock with Fair Valuation and High Potential
↗
August 18, 2025
ACADIA Pharmaceuticals (ACAD) offers strong growth, fair valuation, and solid financial health, making it a top pick for the Affordable Growth investment strategy.
Via
Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Combines Strong Fundamentals with Bullish Technicals for Growth Potential
↗
August 16, 2025
ACADIA Pharmaceuticals (ACAD) shows strong growth fundamentals with rising revenue, EPS, and solid margins, plus a bullish technical breakout, making it a promising stock pick.
Via
Chartmill
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 11, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts
↗
June 05, 2025
Via
Benzinga
Acadia (ACAD) Q2 Revenue Rises 9%
↗
August 06, 2025
Via
The Motley Fool
Topics
Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Q2 2025 Earnings: Revenue Growth Meets Expectations, EPS Beats Estimates
↗
August 06, 2025
Acadia Pharmaceuticals reports Q2 2025 earnings with $264.6M revenue (+9% YoY), EPS beats at $0.16. NUPLAZID & DAYBUE sales grow, reaffirms full-year guidance. Stock up 12.5% in past month.
Via
Chartmill
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
August 06, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
August 05, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
August 04, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
↗
July 30, 2025
Via
Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A High-Growth Biotech Stock with Fair Valuation
↗
July 25, 2025
ACADIA Pharmaceuticals (ACAD) offers strong growth, solid profitability, and fair valuation, making it a top pick for investors seeking affordable growth in biotech.
Via
Chartmill
What Analysts Are Saying About ACADIA Pharmaceuticals Stock
↗
July 24, 2025
Via
Benzinga
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
July 23, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential
↗
July 22, 2025
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a noteworthy stock for growth investors.
Via
Chartmill
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
↗
July 10, 2025
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.
Via
Investor's Business Daily
Topics
Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation
↗
July 04, 2025
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it a compelling candidate for growth...
Via
Chartmill
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
June 25, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential
↗
June 24, 2025
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch for potential breakout opportunities.
Via
Chartmill
13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know
↗
June 23, 2025
Via
Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 17, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Affordable Growth Stock
↗
June 12, 2025
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it an interesting candidate for growth...
Via
Chartmill
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
June 09, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory
↗
June 06, 2025
Acadia wins Nuplazid patent case, extending protection to 2038, as JP Morgan boosts price target ahead of key appeal on the ‘740 COM patent.
Via
Benzinga
Topics
Intellectual Property
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025
June 05, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
May 29, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
May 27, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation
↗
May 22, 2025
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it an interesting stock for growth investors.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
